GlassScriptPhysician profile
William N Harwin
NPI 1164413589
$60,569.86
in general payments reported to CMS, 2019-2025
49 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $36K · 2021: $1,806 · 2022: $1,684 · 2023: $617 · 2024: $18.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $635.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $25,581.24 | 2019-2023 | Enhertu |
| Genzyme Corporation | $9,084.40 | 2019-2023 | |
| Tesaro, INC. | $7,111.59 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $5,867.42 | 2020-2023 | Tagrisso |
| Eisai INC. | $2,623.31 | 2019-2022 | |
| Karyopharm Therapeutics INC. | $2,291.09 | 2020-2022 | |
| Beigene USA, INC. | $1,650.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $999.01 | 2019-2024 | Opdivo, Opdualag |
| Ipsen Bioscience INC. | $850.00 | 2020 | |
| Janssen Scientific Affairs, LLC | $650.00 | 2021 | |
| Celgene Corporation | $522.57 | 2019-2023 | Reblozyl, Opdualag |
| Beigene, LTD. | $450.00 | 2020 | |
| Amgen INC. | $311.94 | 2020-2022 | |
| Janssen Biotech, INC. | $273.15 | 2019-2022 | |
| Incyte Corporation | $261.88 | 2019-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Harwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.